Green Obsession: Trees Towards Cities, Humans Towards Forests

The book follows a discursive thread, alternating dialogues and scientific essays by some of the main protagonists who have contributed to widening the perspective on this subject, helping to raise awareness while protecting the world and its biodiversity. Cities have contributed for centuries to the promotion of some of humanity’s greatest ideas, we must now urgently include them as among the principal players in the environmental debate and at the forefront of any policy tackling and countering – possibly reversing - climate change. Nevertheless, even today one of the most significant technologies capable of absorbing CO2 and restoring our environment is photosynthesis. Planting trees, in addition to protecting existing natural areas and biodiversity, together with de-carbonization, renewable energies, digitalization, smart mobility and the circular economy could be the set of strategies necessary to tackle climate change. Today the effects of the Anthropocene age are ever more visible, changing our environment and affecting every species that lives within it. Green Obsession offers a path to be taken, a hard but still necessary paradigm shift – even for architecture and urbanism – that aims to give a voice to this much needed ecological transition. This book aims to unveil the processes and the complexity involved in the search for a new kind of urbanism, while raising questions and opening old wounds related to the relationship between the human species and Nature and finally putting these fragments together to create a portrait of our era. We need to conceive cities as new green catalysts. Now more than ever, it is essential to act together as separate individuals and professionals, joining the cause as members of the global community with a shared environmental strategy. We all have to open the era of a new alliance between Nature and City

Towards the Development of a Conceptual Framework of BioCities

This edited volume centers around the concept of BioCities, which aim to unify nature and urban spaces in order to reverse the effects of global climate change and inequity. Following this principle, the authors propose multiple approaches for sustainable city growth. The discussed concepts are not only relevant for newly constructed cities, but offer transformative perspectives for existing settlements as well. Placing nature at the forefront of city planning is not an entirely new concept, so the authors build on established ideas like the garden city, green city, eco-city, or smart city. All chapters aim to highlight aspects to develop a city that is a resilient nature-based socio-ecological system. Many of these concepts were formed in an effort to copy the best traits of a forest ecosystem: a home for many different species that build complex communities. Much like many of our forests, urban areas are managed by humans for multifunctional purposes, using living and abiotic components. This viewpoint helps to understand the potential and limitations of sustainable growth. With these chapters, the authors want to inspire planners, ecologists, urban foresters and decision makers of the future

The Enabling Environment for BioCities

The Governing Missions and Mission-Oriented Research and Innovation in the European Union guidelines promoted by the European Commission (EC) are helpful as a starting place for creating the enabling environment for BioCities which follow the principles of natural ecosystems to promote life (Mazzucato 2018, 2019). The strength of mission-oriented policies, defined as systemic public policies that draw on frontier knowledge to attain specific goals, is the empowerment of emergent solutions achieved by: (1) being bold and inspirational with wide social relevance; (2) having a clear direction with targeted, measurable, and time-bound metrics; (3) being ambitious but realistic; (4) being cross-disciplinary and cross-sectoral; and (5) driving multiple bottom-up solutions (Ergas 1987)

Towards the Development of a Conceptual Framework of BioCities

This introductory chapter will evaluate how we have reached the current point in the history of world urbanity, its relationship with nature, and why a fusion between the two is now necessary. In order to define BioCities as cities which follow the principles of natural ecosystems to promote life, we will refer to the extensive knowledge of the history of urban science, the need for cities to be reinvented based on ecological principles, and new methods of analysing and measuring reality through digital systems. This vision of the main functions and traits of BioCities will also serve as a thread and reference for the subsequent chapters which will highlight and elaborate on the different properties of the BioCity vision. The final chapter will draw from this vision the constituting principles of the BioCity and will outline possible pathways of transition towards BioCities

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk